Latest Interim Results News

Adherium Limited has exceeded its 2025 shipment goals for its Hailie Smartinhaler devices, driven by rapid growth in remote patient monitoring activations and improved US Medicare reimbursement policies.

Radiopharm Theranostics has reported promising interim results from its Phase 2b trial of RAD 101, showing high concordance with MRI in brain metastases patients, while progressing multiple other clinical programs and securing a strong cash position to fund operations into 2027.

City Chic Collective reports a robust 71% rise in underlying EBITDA for the first half of FY26, powered by strong ANZ revenue growth and strategic inventory management in the US despite tariff headwinds.

Navigator Global Investments reported steady ownership-adjusted assets under management of USD29 billion for the December 2025 quarter, buoyed by strong hedge fund performance and resilient private markets growth despite the Bardin Hill sale.

Dart Mining NL reports encouraging 2024 diamond drilling results at its Rushworth project in Victoria, revealing multiple wide gold mineralised lodes at the Phoenix Reef prospect. The company plans to resume drilling in 2026, targeting new structural zones identified by recent interpretations.

GPT Group has announced an estimated 12.0 cents per security distribution for the second half of 2025, alongside key dates for investor events in 2026.

Radiopharm Theranostics reports promising interim Phase 2b results for RAD 101, achieving 92% concordance with MRI in detecting brain metastases, paving the way for a pivotal study in 2026.

Dimerix has successfully completed recruitment and dosing of 286 adult patients in its Phase 3 ACTION3 trial evaluating DMX-200 for focal segmental glomerulosclerosis (FSGS), advancing toward regulatory discussions with the FDA.

OncoSil Medical’s interim OSPREY registry data reveals promising survival improvements for patients with unresectable locally advanced pancreatic cancer treated with OncoSil™ plus chemotherapy. The findings suggest a meaningful step forward in a field with limited effective options.

Optiscan Imaging Ltd has initiated Australia’s first intra-operative head and neck cancer imaging study using its advanced InVue® and InForm™ devices, aiming to enhance surgical precision and support FDA regulatory submissions.

Treasury Wine Estates signals a major non-cash impairment on its US assets, expected to wipe out all goodwill in the Americas segment amid softer market growth assumptions.

TruScreen Group Limited reported a 17% decline in first half FY2026 product sales but affirmed full-year revenue guidance at NZ$2.8 million, supported by strategic expansions and a successful NZ$4 million capital raise.